- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical and Economic Consequences of Nonadherence to IV Iron
Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.
EP: 1.Background and Causes of Iron Deficiency Anemia
EP: 2.Pathophysiology of Iron Deficiency Anemia
EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia
EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia
EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis
EP: 6.Oral vs IV Iron in Clinical Practice
EP: 7.FDA-Approved IV Iron Formulations
EP: 8.Factoring in Safety Considerations With IV Iron Products
EP: 9.Adverse Effects Associated With Hypophosphatemia
EP: 10.Clinical Impact of Hypophosphatemia
EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron
EP: 12.Adherence and Time Spent Receiving IV Iron Infusions
EP: 13.Step Edits Associated with IV Iron Therapies
EP: 14.The Future of IV Iron Administration
EP: 15.Closing Thoughts on Iron Deficiency Anemia
Video content above is prompted by the following:
- What are the potential clinical and economic consequences of nonadherence to IV iron therapy?
- How does nonadherence to therapy decrease patient quality of life?
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
